$30.63
-0.32-1.03%
At close: -
$31.06
0.431.40%
After Hours: Nov 7, 6:32 PM EDT
Comments
Loading...
Ultragenyx Pharmaceutical Analyst Ratings and Price Targets | NASDAQ:RARE | Benzinga
Ultragenyx Pharmaceutical Inc has a consensus price target of $88.92 based on the ratings of 24 analysts. The high is $140 issued by Piper Sandler on January 13, 2025. The low is $34 issued by Wedbush on July 14, 2025. The 3 most-recent analyst ratings were released by TD Cowen, Truist Securities, and HC Wainwright & Co. on November 5, 2025, November 5, 2025, and September 9, 2025, respectively. With an average price target of $81.67 between TD Cowen, Truist Securities, and HC Wainwright & Co., there's an implied 162.93% upside for Ultragenyx Pharmaceutical Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
TD Cowen
Truist Securities
HC Wainwright & Co.
Cantor Fitzgerald
Canaccord Genuity
1calculated from analyst ratings
Analyst Ratings for Ultragenyx Pharmaceutical
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
11/05/2025 | 141.47% | TD Cowen | $86 → $75 | Maintains | Buy | |||
11/05/2025 | 189.76% | Truist Securities | $100 → $90 | Maintains | Buy | |||
09/09/2025 | 157.57% | HC Wainwright & Co. | $80 → $80 | Reiterates | Buy → Buy | |||
09/05/2025 | 238.06% | Cantor Fitzgerald | $105 → $105 | Reiterates | Overweight → Overweight | |||
08/08/2025 | 312.11% | Canaccord Genuity | $136 → $128 | Maintains | Buy | |||
08/06/2025 | 238.06% | Cantor Fitzgerald | $112 → $105 | Maintains | Overweight | |||
07/28/2025 | 157.57% | HC Wainwright & Co. | → $80 | Assumes | → Buy | |||
07/14/2025 | 9.47% | Wedbush | $35 → $34 | Maintains | Neutral | |||
07/14/2025 | 77.08% | Morgan Stanley | $65 → $55 | Maintains | Overweight | |||
07/10/2025 | 109.27% | Wells Fargo | $88 → $65 | Maintains | Overweight | |||
06/20/2025 | 106.05% | Guggenheim | $64 → $64 | Reiterates | Buy → Buy | |||
05/28/2025 | 109.27% | William Blair | → $65 | Initiates | → Outperform | |||
05/09/2025 | 109.27% | Morgan Stanley | $64 → $65 | Maintains | Overweight | |||
03/27/2025 | 276.69% | JP Morgan | $104 → $117 | Maintains | Overweight | |||
03/17/2025 | 270.25% | Piper Sandler | $140 → $115 | Maintains | Overweight | |||
02/26/2025 | 279.91% | Cantor Fitzgerald | $118 → $118 | Reiterates | Overweight → Overweight | |||
02/18/2025 | 205.86% | HC Wainwright & Co. | $95 → $95 | Reiterates | Buy → Buy | |||
02/18/2025 | 337.86% | Canaccord Genuity | $121 → $136 | Maintains | Buy | |||
02/14/2025 | 205.86% | HC Wainwright & Co. | $95 → $95 | Reiterates | Buy → Buy | |||
01/22/2025 | 279.91% | Cantor Fitzgerald | $118 → $118 | Reiterates | Overweight → Overweight | |||
01/13/2025 | 350.74% | Piper Sandler | $135 → $140 | Maintains | Overweight | |||
01/13/2025 | 54.54% | Wedbush | $46 → $48 | Reiterates | Neutral → Neutral | |||
12/24/2024 | 205.86% | HC Wainwright & Co. | $95 → $95 | Reiterates | Buy → Buy | |||
12/20/2024 | 183.32% | Wells Fargo | $75 → $88 | Maintains | Overweight | |||
11/21/2024 | 228.4% | JP Morgan | $105 → $102 | Maintains | Overweight | |||
11/12/2024 | 289.57% | Canaccord Genuity | $121 → $121 | Maintains | Buy | |||
11/06/2024 | 289.57% | Canaccord Genuity | $109 → $121 | Maintains | Buy | |||
11/06/2024 | 147.91% | RBC Capital | $77 → $77 | Reiterates | Outperform → Outperform | |||
11/06/2024 | 273.47% | Cantor Fitzgerald | $116 → $116 | Reiterates | Overweight → Overweight | |||
11/06/2024 | 205.86% | HC Wainwright & Co. | $82 → $95 | Maintains | Buy | |||
10/22/2024 | 273.47% | Cantor Fitzgerald | $116 → $116 | Reiterates | Overweight → Overweight | |||
10/21/2024 | 135.03% | TD Cowen | $61 → $73 | Maintains | Buy | |||
10/01/2024 | 273.47% | Cantor Fitzgerald | $116 → $116 | Reiterates | Overweight → Overweight | |||
09/26/2024 | 147.91% | RBC Capital | $77 → $77 | Reiterates | Outperform → Outperform | |||
09/20/2024 | 273.47% | Cantor Fitzgerald | $116 → $116 | Reiterates | Overweight → Overweight | |||
09/16/2024 | 273.47% | Cantor Fitzgerald | $116 → $116 | Reiterates | Overweight → Overweight | |||
08/05/2024 | 160.79% | Barclays | $83 → $81 | Maintains | Overweight | |||
08/02/2024 | 141.47% | Wells Fargo | $72 → $75 | Maintains | Overweight | |||
08/02/2024 | 144.69% | Goldman Sachs | $67 → $76 | Maintains | Buy | |||
08/02/2024 | 273.47% | Cantor Fitzgerald | $115 → $116 | Maintains | Overweight | |||
08/02/2024 | 48.1% | Wedbush | $43 → $46 | Maintains | Neutral | |||
07/23/2024 | 257.37% | Canaccord Genuity | $111 → $111 | Maintains | Buy | |||
07/22/2024 | 270.25% | Cantor Fitzgerald | $115 → $115 | Reiterates | Overweight → Overweight | |||
07/18/2024 | 44.88% | Wedbush | $45 → $45 | Reiterates | Neutral → Neutral | |||
06/12/2024 | 270.25% | Cantor Fitzgerald | $115 → $115 | Reiterates | Overweight → Overweight | |||
06/06/2024 | 115.71% | Goldman Sachs | $56 → $67 | Upgrade | Neutral → Buy | |||
05/31/2024 | 54.54% | Wedbush | $47 → $48 | Maintains | Neutral | |||
05/31/2024 | 144.69% | B of A Securities | $83 → $76 | Maintains | Buy | |||
05/31/2024 | 257.37% | Canaccord Genuity | $109 → $111 | Maintains | Buy | |||
05/31/2024 | 270.25% | Cantor Fitzgerald | $107 → $115 | Maintains | Overweight | |||
05/31/2024 | 308.89% | Stifel | $124 → $127 | Maintains | Buy | |||
05/31/2024 | 131.81% | Baird | $68 → $72 | Maintains | Outperform | |||
05/06/2024 | 250.93% | Canaccord Genuity | $111 → $109 | Maintains | Buy | |||
05/03/2024 | 244.49% | Cantor Fitzgerald | $107 → $107 | Reiterates | Overweight → Overweight | |||
05/03/2024 | 51.32% | Wedbush | $48 → $47 | Maintains | Neutral | |||
04/24/2024 | 96.39% | TD Cowen | $59 → $61 | Maintains | Buy | |||
04/22/2024 | 147.91% | RBC Capital | → $77 | Initiates | → Outperform | |||
04/17/2024 | 54.54% | Wedbush | $48 → $48 | Reiterates | Neutral → Neutral | |||
04/16/2024 | 54.54% | Wedbush | $48 → $48 | Reiterates | Neutral → Neutral | |||
04/05/2024 | 244.49% | Cantor Fitzgerald | $107 → $107 | Reiterates | Overweight → Overweight | |||
03/18/2024 | 196.2% | JP Morgan | $88 → $92 | Maintains | Overweight | |||
02/27/2024 | 244.49% | Cantor Fitzgerald | $107 → $107 | Reiterates | Overweight → Overweight | |||
02/27/2024 | 183.32% | JP Morgan | $84 → $88 | Maintains | Overweight | |||
02/21/2024 | 257.37% | Canaccord Genuity | $110 → $111 | Maintains | Buy | |||
02/16/2024 | 54.54% | Wedbush | $47 → $48 | Maintains | Neutral | |||
02/15/2024 | 267.03% | Cantor Fitzgerald | $114 → $114 | Reiterates | Overweight → Overweight | |||
01/30/2024 | 118.93% | Baird | $57 → $68 | Maintains | Outperform | |||
01/19/2024 | 267.03% | Cantor Fitzgerald | $114 → $114 | Reiterates | Overweight → Overweight | |||
12/08/2023 | 131.81% | Wells Fargo | → $72 | Initiates | → Overweight | |||
11/03/2023 | 170.44% | Morgan Stanley | $90 → $84 | Maintains | Overweight | |||
10/25/2023 | 318.54% | Piper Sandler | $135 → $130 | Maintains | Overweight | |||
10/10/2023 | 189.76% | Morgan Stanley | $95 → $90 | Maintains | Overweight | |||
09/25/2023 | 267.03% | Cantor Fitzgerald | → $114 | Reiterates | Overweight → Overweight | |||
08/04/2023 | 205.86% | Morgan Stanley | $95 → $95 | Reiterates | Overweight → Overweight | |||
08/01/2023 | 164.01% | HC Wainwright & Co. | → $82 | Reiterates | Buy → Buy | |||
06/14/2023 | 209.08% | Credit Suisse | → $96 | Assumes | → Outperform | |||
06/07/2023 | 328.2% | Citigroup | $130 → $133 | Maintains | Buy | |||
06/06/2023 | 157.57% | Evercore ISI Group | $60 → $80 | Upgrade | In-Line → Outperform | |||
06/06/2023 | 64.2% | Wedbush | $48 → $51 | Maintains | Neutral | |||
05/08/2023 | 54.54% | Wedbush | $47 → $48 | Maintains | Neutral | |||
05/05/2023 | 318.54% | Citigroup | $130 → $130 | Maintains | Buy | |||
05/05/2023 | 209.08% | Credit Suisse | → $96 | Reiterates | → Outperform | |||
04/26/2023 | 267.03% | Cantor Fitzgerald | → $114 | Initiates | → Overweight | |||
03/18/2023 | 318.54% | Citigroup | $135 → $130 | Maintains | Buy | |||
02/17/2023 | 209.08% | Credit Suisse | → $96 | Reiterates | → Outperform | |||
02/17/2023 | 83.52% | Baird | $50 → $57 | Maintains | Outperform | |||
02/03/2023 | 205.86% | Morgan Stanley | $100 → $95 | Maintains | Overweight | |||
01/18/2023 | 189.76% | Canaccord Genuity | → $90 | Assumes | → Buy | |||
01/09/2023 | 334.64% | Citigroup | $138 → $135 | Maintains | Buy | |||
12/30/2022 | 164.01% | HC Wainwright & Co. | → $82 | Assumes | → Buy |
FAQ
What is the target price for Ultragenyx Pharmaceutical (RARE) stock?
The latest price target for Ultragenyx Pharmaceutical (NASDAQ:RARE) was reported by TD Cowen on November 5, 2025. The analyst firm set a price target for $75.00 expecting RARE to rise to within 12 months (a possible 141.47% upside). 26 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Ultragenyx Pharmaceutical (RARE)?
The latest analyst rating for Ultragenyx Pharmaceutical (NASDAQ:RARE) was provided by TD Cowen, and Ultragenyx Pharmaceutical maintained their buy rating.
When was the last upgrade for Ultragenyx Pharmaceutical (RARE)?
The last upgrade for Ultragenyx Pharmaceutical Inc happened on June 6, 2024 when Goldman Sachs raised their price target to $67. Goldman Sachs previously had a neutral for Ultragenyx Pharmaceutical Inc.
When was the last downgrade for Ultragenyx Pharmaceutical (RARE)?
There is no last downgrade for Ultragenyx Pharmaceutical.
When is the next analyst rating going to be posted or updated for Ultragenyx Pharmaceutical (RARE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ultragenyx Pharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ultragenyx Pharmaceutical was filed on November 5, 2025 so you should expect the next rating to be made available sometime around November 5, 2026.
Is the Analyst Rating Ultragenyx Pharmaceutical (RARE) correct?
While ratings are subjective and will change, the latest Ultragenyx Pharmaceutical (RARE) rating was a maintained with a price target of $86.00 to $75.00. The current price Ultragenyx Pharmaceutical (RARE) is trading at is $31.06, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
